Alexion Antibody Technologies, Inc. Company Profile

08:07 EDT 22nd October 2017 | BioPortfolio

Alexion Antibody Technologies, Inc. (AAT) is a wholly owned subsidiary of Alexion Pharmaceuticals [ALXN]. AAT is engaged in discovering and developing a portfolio of antibody therapeutics targeting severe unmet medical needs including cancer, autoimmune disorders, and inflammation. AAT was formed in September 2000 from the merger of the discovery platform of Prolifaron, Inc. with the established antibody development capacity of Alexion Pharmaceuticals, forming a powerhouse in antibody discovery and development. Alexion is approaching full integration, from discovery through commercialization.


3985 Sorrento Valley Blvd Ste, A
San Diego
United States of America


Phone: (858) 550-3490
Fax: (858) 550-3498

News Articles [872 Associated News Articles listed on BioPortfolio]

Alexion, Moderna end partnership

Moderna Therapeutics, a clinical stage biotechnology company that is pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, prov...

Alexion and Sema4 announce strategic partnership

Alexion Pharmaceuticals, Inc. and Sema4 have announced a strategic partnership to leverage their shared experience in data science and systems biology to accelerate rare disease diagnosis and therapeu...

Alexion restructures, cuts workforce 20%

Alexion Pharmaceuticals announced an operational plan to re-align the global organization with its refocused corporate strategy. The plan is expected to deliver approximately $270 million in GAAP and ...

STAT Plus: Pharmalittle: Alexion is being probed by HHS; Shkreli was depressed when his fund ‘imploded’

Alexion Pharmaceuticals is under investigation by the Office of the Inspector General of the U.S. Department of Health and Human Services.

Alexion cutting 600 jobs and moving headquarters in major shakeup

Alexion, once one of biotech's biggest success stories, is eliminating 20 percent of its global workforce as it struggles to map out a brighter future.

Alexion ends Moderna mRNA pact

Alexion Pharmaceuticals says it is reducing R&D operations and terminating mRNA-focused preclinical partnerships.

Broad-based shakeup at Alexion will see fifth of workforce fired

Connecticut, USA-based Alexion Pharmaceuticals has announced a wide-ranging restructuring plan in which…

Alexion snags EU yes for new Soliris indication

The European Commission extended its approval of Soliris, allowing Alexion to sell the drug for another rare condition.

PubMed Articles [1188 Associated PubMed Articles listed on BioPortfolio]

Protein Arrays I: Antibody Arrays.

Antibody arrays represent one of the very early protein array systems where antibodies are used to capture and detect target proteins in a high-throughput platform. The development of high-quality ant...

Dynamics of 8G12 competitive antibody in "prime-boost" vaccination of Hepatitis E vaccine.

Hepatitis E virus still poses a great threat to public health worldwide. To date, Hecolin® is the only licensed HEV vaccine in China. Total anti-HEV antibody has been used to reflect vaccine induced ...

Protein engineering to increase the potential of a therapeutic antibody Fab for long-acting delivery to the eye.

To date, ocular antibody therapies for the treatment of retinal diseases rely on injection of the drug into the vitreous chamber of the eye. Given the burden for patients undergoing this procedure, le...

Challenges and opportunities for the future of monoclonal antibody development: improving safety assessment and reducing animal use.

The market for biotherapeutic monoclonal antibodies (mAbs) is large and is growing rapidly. However, attrition poses a significant challenge for the development of mAbs, and for biopharmaceuticals in ...

Immunoblotting and Immunodetection.

Immunoblotting (western blotting) is used to identify specific antigens recognized by polyclonal or monoclonal antibodies. This unit provides protocols for all steps, starting with solubilization of t...

Clinical Trials [1689 Associated Clinical Trials listed on BioPortfolio]

Application of Monitoring and Intervention Technologies in Suboptimal Health Status

The purpose of this study is to use monitoring and intervention technologies in suboptimal health status in a general population in China and evaluate the effectiveness of these technologi...

Wheeze Detection in Adults During Dynamic Bronchial Situations Measured by PulmoTrack® 2010 With WIM-PC™ Technologies Recording

The PulmoTrack® 2010 with WIM-PC™ Technologies device, indicated for acoustic pulmonary function measurement that quantifies the presence of wheezing. This study was designed in order t...

JCV Antibody Program (STRATIFY-1)

Study conducted to define the prevalence of Serum JC Antibody in relapsing MS patients receiving Tysabri or being considered for such treatment. Analytically validate the JCV antibody ass...

Expanded Access Study of Iodine-131 Anti-B1 Antibody

The primary objective of this study is to make Iodine-131 Anti-B1 Antibody more broadly available to patients. Secondary endpoints of the study will be to obtain additional information on...

JCV Antibody Program (STRATIFY-2)

Define the sero prevalence of JCV Antibody in the MS population and potentially stratify patients into lower or higher risk for developing PML based on antibody status.

Companies [1617 Associated Companies listed on BioPortfolio]

Alexion Antibody Technologies, Inc.

Alexion Antibody Technologies, Inc. (AAT) is a wholly owned subsidiary of Alexion Pharmaceuticals [ALXN]. AAT is engaged in discovering and developing a portfolio of antibody therapeutics targeting se...

Alexion Pharmaceuticals Inc.

Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare disorders. Alexion developed ...

Alexion Pharmaceuticals Incorporated

Alexion is a global biopharmaceutical company that combines groundbreaking science with a steadfast commitment to meeting the needs of patients living with severe, life-threatening and often ultra-rar...

Antibody Solutions Inc

Antibody Solutions Inc., based in Mountain View in the San Francisco Bay Area, offers quality antibody development, antibody manufacture and immunoassay development that are optimized for your specifi...

Takeda San Francisco Inc.

Takeda San Francisco was established in November 2007 and supports Takeda's therapeutic antibody research aiming to build antibody technology platforms based on technologies such as discovery and ...

More Information about "Alexion Antibody Technologies, Inc." on BioPortfolio

We have published hundreds of Alexion Antibody Technologies, Inc. news stories on BioPortfolio along with dozens of Alexion Antibody Technologies, Inc. Clinical Trials and PubMed Articles about Alexion Antibody Technologies, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Alexion Antibody Technologies, Inc. Companies in our database. You can also find out about relevant Alexion Antibody Technologies, Inc. Drugs and Medications on this site too.

Quick Search

Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Autoimmune Disorders
Autoimmune disorders are conditions that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune disorders. Normally the immune system's white blood cells help protect ...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Corporate Database Quicklinks

Searches Linking to this Company Record